이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

INKON Life Technology 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Wen Peng

최고 경영자

CN¥1.8m

총 보상

CEO 급여 비율	n/a
CEO 임기	3.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

INKON Life Technology Co., Ltd. (SZSE:300143) Looks Just Right With A 26% Price Jump

Sep 30

Returns Are Gaining Momentum At INKON Life Technology (SZSE:300143)

Sep 29

INKON Life Technology (SZSE:300143) Seems To Use Debt Quite Sensibly

Sep 10

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

Apr 23

What You Can Learn From INKON Life Technology Co., Ltd.'s (SZSE:300143) P/S

Mar 28

CEO

Wen Peng (56 yo)

3.1yrs

테뉴어

CN¥1,778,900

보상

Mr. Wen Peng has been General Manager of INKON Life Technology Co., Ltd. since August 25, 2021 and has been its Non-Independent Director since September 14, 2020. Mr. Peng served as the Deputy General Mana...

리더십 팀

이름	위치	테뉴어	보상	소유권
Wen Peng	GM & Director	3.1yrs	CN¥1.78m	데이터 없음
Lan Jiang	Financial Director	less than a year	CN¥202.10k	데이터 없음
Zelin Liu	Board Secretary	1.8yrs	CN¥506.20k	데이터 없음
Hongbo Li	Deputy General Manager	4.4yrs	CN¥1.05m	데이터 없음
Jinchen Xie	Accounting Supervisor	no data	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: 300143 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Wen Peng	GM & Director	4yrs	CN¥1.78m	데이터 없음
Lixia Tan	Chairman	5.3yrs	데이터 없음	데이터 없음
Xudong Shen	Non-Independent Director	5.3yrs	CN¥1.26m	데이터 없음
Mianshun Pan	Non-Independent Director	4yrs	CN¥457.60k	데이터 없음
Wenwen Gong	Chairman of the Supervisory Board	4yrs	데이터 없음	데이터 없음
Xudong Wang	Employee Representative Supervisor	4.8yrs	데이터 없음	데이터 없음
Xiaoman Chen	Independent Director	less than a year	CN¥30.00k	데이터 없음
Yuan Du	Independent Director	less than a year	CN¥30.00k	데이터 없음
Feng Jiang	Independent Director	less than a year	CN¥30.00k	데이터 없음

4.0yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: 300143 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

INKON Life Technology 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

High number of new directors

High number of new directors

High number of new and inexperienced directors

Recent updates

INKON Life Technology Co., Ltd. (SZSE:300143) Looks Just Right With A 26% Price Jump

INKON Life Technology Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024

Investor sentiment improves as stock rises 32%

Returns Are Gaining Momentum At INKON Life Technology (SZSE:300143)

Now 23% undervalued

INKON Life Technology (SZSE:300143) Seems To Use Debt Quite Sensibly

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.045 (vs CN¥0.057 in 2Q 2023)

Investor sentiment improves as stock rises 15%

INKON Life Technology Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

INKON Life Technology Co., Ltd. Just Missed EPS By 16%: Here's What Analysts Think Will Happen Next

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

INKON Life Technology Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

What You Can Learn From INKON Life Technology Co., Ltd.'s (SZSE:300143) P/S

Price target decreased by 7.9% to CN¥12.27

INKON Life Technology Co., Ltd. (SZSE:300143) announces an Equity Buyback for CNY 80 million worth of its shares.

INKON Life Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.013 in 3Q 2022)

Now 21% undervalued after recent price drop

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

INKON Life Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.036 in 2Q 2022)

Full year 2022 earnings released: CN¥1.01 loss per share (vs CN¥0.57 loss in FY 2021)

Price target decreased to CN¥14.25

High number of new directors

High number of new directors

Qingdao Haiyingkang Investment Co., Ltd. and INKON Life Technology Co., Ltd. (SZSE:300143) agreed to acquire Shenzhen Shengzhong Investment Enterprise (Limited Partnership) from a group of shareholders for CNY 87.7 million.

Third quarter 2022 earnings released: EPS: CN¥0.013 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.036 (vs CN¥0.019 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥22.88

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.026 in 3Q 2020)

Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) for CNY 1.3 million.

Price target decreased to CN¥21.84

Second quarter 2021 earnings released: EPS CN¥0.019 (vs CN¥0.071 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.018 (vs CN¥0.021 loss in 1Q 2020)

INKON Life Technology Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥18.00

New 90-day low: CN¥20.30

New 90-day low: CN¥21.84

New 90-day low: CN¥22.19

Third quarter earnings released

First half earnings released

New 90-day high - CN¥25.53

INKON Life Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

INKON Life Technology Co., Ltd. announced that it has received CNY 732.939997 million in funding from Qingdao Yingkang Medical Investment Co., Ltd.

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령